These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Static Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141 [TBL] [Abstract][Full Text] [Related]
28. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related]
29. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423 [TBL] [Abstract][Full Text] [Related]
30. Clinical implications of molecular analysis in diffuse glioma stratification. Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651 [TBL] [Abstract][Full Text] [Related]
31. Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma. Kim SW; Park BJ; Kim HS; Na K In Vivo; 2021; 35(2):921-927. PubMed ID: 33622884 [TBL] [Abstract][Full Text] [Related]
34. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T; Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363 [TBL] [Abstract][Full Text] [Related]
35. Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas. Rajmohan KS; Sugur HS; Shwetha SD; Pandey P; Arivazhagan A; Santosh V Neurol India; 2020; 68(4):832-837. PubMed ID: 32859823 [TBL] [Abstract][Full Text] [Related]
36. Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma. Wong D; Lee TH; Lum A; Tao VL; Yip S Acta Neuropathol Commun; 2022 May; 10(1):70. PubMed ID: 35526077 [TBL] [Abstract][Full Text] [Related]
37. Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Yao J; Hagiwara A; Raymond C; Shabani S; Pope WB; Salamon N; Lai A; Ji M; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM Sci Rep; 2020 Jul; 10(1):11922. PubMed ID: 32681084 [TBL] [Abstract][Full Text] [Related]
38. Foundations of the Diagnosis and Management of Low-Grade Gliomas. Norman S; Juthani RG; Magge R World Neurosurg; 2022 Oct; 166():306-312. PubMed ID: 36192862 [TBL] [Abstract][Full Text] [Related]
39. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]